Chiesi Farmaceutici S.p.A. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Side Effects and How the Drug CHF6467 Administered Via…Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects

   Primary and study completion pushed from Aug 11, 2026 to Feb 28, 2027

   Chiesi Farmaceutici S.p.A.·Phase 1· NCT07163182· Registry history of NCT07163182 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

2. Notable

   FOSteR · Incidence of Skin Cancers · Epidermolysis Bullosa…FOSteR · Incidence of Skin Cancers · Epidermolysis Bullosa Receiving Filsuvez

   Enrollment reduced: 580 → 170 participants

   Also in this update: Sponsor changed: Amryt Pharma to Chiesi Farmaceutici S.p.A.; Trial sites expanded: 5 → 12 locations

   Chiesi Farmaceutici S.p.A.·Not specified· NCT06423573· Registry history of NCT06423573 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.